Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

Others

HeartSciences (HSCS) Change in Receivables (2022 - 2025)

HeartSciences filings provide 3 years of Change in Receivables readings, the most recent being -$4350.0 for Q3 2025.

On a quarterly basis, Change in Receivables changed N/A to -$4350.0 in Q3 2025 year-over-year; TTM through Oct 2025 was $10800.0, a N/A change, with the full-year FY2025 number at $4350.0, changed N/A from a year prior.
Change in Receivables hit -$4350.0 in Q3 2025 for HeartSciences, down from $4350.0 in the prior quarter.
In the past five years, Change in Receivables ranged from a high of $10800.0 in Q1 2024 to a low of -$4350.0 in Q3 2025.
Median Change in Receivables over the past 3 years was $1014.5 (2022), compared with a mean of $2119.8.